ibrutinib
abbvie,janssen
[' ibru', 'cll']
excellent study looking at overall survival in patients receiving ibrutinib with concurrent cyp3a inducers &amp; inhibitors. age &amp; being on cyp3a inducer (steroids were the most common) = worse os in multivariable. still important in settings where next-gen btki not available. #ash22 
#lymsm & #mmsm hematologist & patient-reported outcomes researcher @CUHematology. Founder of https://t.co/kN6qeGXfg5, @inTrainingDoc & @inHouseMag. ??????